Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal net revenue growth of 23% to $92.9 million MACI® net revenue growth of 23% to $84.1 million Burn Care net revenue of $8.8 million Gross margin of 79% Net income increased 17% to $23.2 million Non-GAAP...

The Company delivered a strong set of results, with record net gaming revenueof €224.1 million and Adj. EBITDA of €13.8 million for FY 2025Total revenue was €57.1 mm in Q4 2025, while net gaming revenue1 was €60.7 mm, 15% above Q4 2024. Mexico revenue was €29.4 mm in Q4 2025, while net gaming revenue was €32.8 mm, 31% above Q4 2024. Adj. EBITDA reached €6.7 mm in Q4 2025, €4.8 mm above Q4 2024. Net loss was €1.8 mm in 2025 versus a net income of €3.9 mm in 2024. Total cash position of €50.0 mm and no financial debt as of December 31, 2025. Outlook for FY 2026: Net gaming revenue of €235-245 mm and Adj. EBITDA2 of €15-20 mm. 391 thousand repurchased shares for an aggregate amount of $2.7 mm under the Company’s share buyback plan through February 25, 2026.Madrid, Spain and Tel Aviv, Israel, February 26, 2025 – (GLOBE NEWSWIRE) Codere...

Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025 Eighth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the number one cannabis brand 1 Industry leading balance sheet with $832 million in cash and cash equivalents and short-term investments TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 fourth quarter and full-year business results. “Cronos delivered record net revenue, gross profit and Adjusted EBITDA in 2025, reflecting the continued strength of our core business and the progress we are making towards our strategic priorities. We achieved record...

ATHENS, Greece, Feb. 26, 2026 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported net income of $3.1 million and net income attributable to common stockholders of $1.7 million for the fourth quarter of 2025. This compares to net income of $9.7 million and net income attributable to common stockholders of $8.3 million for the fourth quarter of 2024. Earnings per share for the fourth quarter of 2025 were $0.02 basic and diluted, compared to $0.07 basic and $0.02 diluted in the same quarter of 2024. Time charter revenues were $52.1 million for the fourth quarter of 2025, compared to $57.1 million for the same quarter of 2024. The decrease was primarily attributable to the sale of two vessels in 2025...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025. Anika reported fourth quarter revenue of $30.6 million, flat compared to the fourth quarter of 2024. Gross margin expanded to 63%, driven...

– Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch– Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended December 31, 2025 (Fiscal Q1 2026). “Conavi is approaching a key inflection point with anticipated U.S. FDA 510(k) clearance of our next-generation Novasight Hybrid™ system in the first half of 2026,” said Thomas Looby, President and Chief Executive Officer of...

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025 GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025 Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025 Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025 Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growth Company provides full year 2026 revenue and adjusted fully diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc....

– Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 – – Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 – – Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 – – ATI-2138, Aclaris’ Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model – WAYNE, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...

SHELTON, Conn., Feb. 26, 2026 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended December 31, 2025 were $47.5 million compared to $45.9 million in the fourth quarter of 2024, an increase of 3%. Net sales for the year ended December 31, 2025 were $196.5 million compared to $194.5 million in 2024, an increase of 1%. Net income was $1.9 million, or $0.46 per diluted share, for the quarter ended December 31, 2025 compared to $1.7 million, or $0.41 per diluted share, for the same period in 2024, an increase of 10% in net income and 12% in diluted earnings per share. Net income for the year ended December 31, 2025, was $10.2 million, or $2.49 per diluted share, compared to $10.0 million, or $2.45 per diluted share, for 2024, an increase of 2% in both net income and diluted...

ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March 26, 2026. Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor...